Bayer said it will voluntarily withdraw its follicular lymphoma drug Aliqopa from the US after a confirmatory trial disappointment, marking the third PI3K inhibitor to be pulled in recent years.
A Bayer spokesperson told Endpoints News in an email that the Phase III CHRONOS-4 trial of Aliqopa plus standard immunotherapy in patients with relapsed indolent non-Hodgkin lymphoma did not meet its primary endpoint, which is listed as progression-free survival on ClinicalTrials.gov. Topline data from the confirmatory study are yet to be published.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.